AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Epinephrine auto-injectors, widely prescribed for anaphylaxis from severe allergic reactions to food, insect bites and even strenuous exercise, make up a $2.12B market worldwide. The market is expected to grow 10.2% to $4.60B in the next decade. North America dominated the global market with a share of 63.5% in 2023.
Severe allergies and asthma affect millions and have been increasing at a significant rate globally, fueling the demand for epinephrine auto-injectors. Asthma affects around 4.0%-6.0% of adults and about 10.0% of children, in 2022, according to The National Center for Biotechnology Information. Apart from anaphylaxis, auto-injectors are used to treat cardiac arrests, respiratory disorders, and chronic conditions
Currently, patients are advised to replace their auto-injectors annually, as the epinephrine degrades and is less effective. The clock starts the day the devices are manufactured, and ticks on as the devices are transported and stored on pharmacy shelves, which could be several months before patients have them in hand. This means that a patient could receive an auto-injector for which there are just a few months before it expires when they buy it at their pharmacy.
Purchasing replacement auto-injector can be costly, especially if several twin-packs are needed in home, school, camp and other frequented locations.
Rx Bandz’ research maximizes the hydraulic design of its MiniJect® auto-injector. Rx Bandz expects that its patented process of reducing drug oxidation can be applied to many other oxygen-sensitive therapeutics.
Stephen Harhen, Rx Bandz Chief Technology and Innovation Officer said, “The data confirmed what we could see in the color change of epinephrine. The unprotected drug under accelerated storage turned brown after just 1 month of accelerated testing. However, the epinephrine protected by our patented system remained clear, which indicates it continues to be effective. We are now testing how long our process will protect epinephrine. While tests are on-going, it appears that we’re on track to achieve a significantly improved shelf-life.”
Dr. Yosyong Surakitbanharn, Rx Bandz’ Chief Drug Development Officer, led the studies. He is among the world’s leading researchers in epinephrine.
The Rx Bandz team is also reviewing the effectiveness of its proprietary process in commercially available products.
About Rx Bandz
Rx Bandz is a privately-held, woman-led biotech with its laboratory in Fairfield, NJ. Rx Bandz is developing the next generation of patient-centric auto-injectors to deliver a wide range of injectable medications around the world. Its MiniJect is the world’s smallest auto-injector that is safer, faster and easier-to-use than traditional auto-injectors. With products in development to treat numerous emergency medical conditions, Rx Bandz initially focused on delivering epinephrine to treat anaphylactic shock. The company is also formulating new drugs of various viscosities and molecular sizes for administration in its 1 ml to 5 ml auto-injectors.
For more information, see the company’s website at www.rxbandz.com
Myrna Walsh
RxBandz.com
+1 617-347-3475
email us here
Visit us on social media:
LinkedIn
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
